Physician profile
Marni Lynne Martinez
NPI 1669756508
$14,441.63
in general payments reported to CMS, 2019-2025
31 companies · $3,116 in 2025
The $3,116 reported for 2025 was more than what 96% of Adult Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $186).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,896 · 2022: $2,207 · 2023: $2,973 · 2024: $4,250 · 2025: $3,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,220.68 |
| Education | $117.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,976.12 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,488.36 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,301.32 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $1,027.98 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Qol Medical, LLC | $796.59 | 2021-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $765.53 | 2024-2025 | Omvoh |
| Celgene Corporation | $754.37 | 2021-2024 | Zeposia |
| Genzyme Corporation | $511.79 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $490.72 | 2021-2024 | Stelara, Remicade, Tremfya |
| Madrigal Pharmaceuticals | $488.95 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $426.11 | 2022-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $395.36 | 2024-2025 | Zenpep, Vowst |
| Celltrion USA INC. | $303.90 | 2024-2025 | Vegzelma, Zymfentra |
| Nestle Healthcare Nutrition INC. | $260.69 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $260.05 | 2021-2024 | Ocaliva |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $182.06 | 2021-2025 | |
| Redhill Biopharma INC. | $173.66 | 2021-2023 | Talicia, Aemcolo, Movantik |
| E.R. Squibb & Sons, L.L.C. | $144.07 | 2022-2024 | |
| Daiichi Sankyo INC. | $119.69 | 2021-2022 | |
| Novo Nordisk INC | $117.14 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $102.17 | 2024-2025 | Iqirvo |
| Pfizer INC. | $78.09 | 2023-2024 | |
| Pharmacosmos Therapeutics INC. | $76.71 | 2021 | |
| Amgen INC. | $39.77 | 2021-2022 | |
| Braintree Laboratories, INC. | $39.73 | 2022-2023 | Sutab |
| Ironwood Pharmaceuticals, INC | $33.09 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $24.49 | 2024 | Dupixent |
| Ethicon US, LLC | $17.79 | 2021 | |
| Fujifilm Healthcare Americas Corporation | $16.91 | 2025 | |
| Organon LLC | $14.55 | 2025 | Hadlima |
| Phathom Pharmaceuticals, INC. | $13.87 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marni Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.